Roger Jeffs Net Worth

The estimated Net Worth of Roger Jeffs is at least $75.5 Million dollars as of 12 July 2024. Roger Jeffs owns over 8,053 units of Axsome Therapeutics Inc stock worth over $74,547,380 and over the last 20 years he sold AXSM stock worth over $693,510. In addition, he makes $276,310 as Lead Independent Director at Axsome Therapeutics Inc.

Roger Jeffs AXSM stock SEC Form 4 insiders trading

Roger has made over 333 trades of the Axsome Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 8,053 units of AXSM stock worth $100,904 on 12 July 2024.

The largest trade he's ever made was buying 139,665 units of Axsome Therapeutics Inc stock on 14 December 2023 worth over $1,000,001. On average, Roger trades about 7,934 units every 18 days since 2004. As of 12 July 2024 he still owns at least 818,932 units of Axsome Therapeutics Inc stock.

You can see the complete history of Roger Jeffs stock trades at the bottom of the page.

Roger Jeffs biography

Dr. Roger A. Jeffs Ph.D. serves as Lead Independent Director of the Company. Dr. Jeffs is currently the Co-Founder and Vice Chairman of Kriya Therapeutics since October 2019. Dr. Jeffs was previously at United Therapeutics Corporation where he worked for 18 years until 2016. Dr. Jeffs joined United Therapeutics Corporation during its inception phase in 1998 as Director of Research, Development, and Medical and served as its President and Chief Operating Officer from 2001 to 2014, and President and co-CEO from 2015-2016, and was a member of the Board of Directors from 2001 through 2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of 6 products for rare diseases, and managed the commercial effort that led to a consistent >20% CAGR and $1.5B revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co. where he held roles in clinical development.

What is the salary of Roger Jeffs?

As the Lead Independent Director of Axsome Therapeutics Inc, the total compensation of Roger Jeffs at Axsome Therapeutics Inc is $276,310. There are 6 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.

What's Roger Jeffs's mailing address?

Roger's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.

Insiders trading at Axsome Therapeutics Inc

Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony, and Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.

What does Axsome Therapeutics Inc do?

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.

Complete history of Roger Jeffs stock trades at Albireo Pharma Inc, Axsome Therapeutics Inc, Sangamo Therapeutics Inc, United Therapeutics Corp, Liquidia Corp, and Axovant Gene Therapies

Axsome Therapeutics Inc executives and stock owners

Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:

• Herriot Tabuteau,
  Chairman of the Board, President, Chief Executive Officer, Founder
• David Marek,
  Chief Commercial Officer
• Nick Pizzie,
  Chief Financial Officer
• Dr. Herriot Tabuteau M.D.,
  Founder, Chairman, CEO & Pres
• Mark L. Jacobson,
  COO & Sec.
• Nick Pizzie CPA, M.B.A.,
  Chief Financial Officer
• Roger Jeffs,
  Lead Independent Director
• Mark Saad,
  Independent Director
• Mark Coleman,
  Independent Director
• Amanda Jones,
  Senior Vice President - Clinical Research
• Cedric O'Gorman,
  Senior Vice President - Clinical Development and Medical Affairs
• Mark Jacobson,
  Chief Operating Officer
• Joseph Debrah-Afful CPA, M.B.A.,
  Director of Fin.
• Kevin Laliberte Pharm.D.,
  Exec. VP of Product Strategy
• Lori Englebert M.B.A.,
  Sr. VP of Commercial & Bus. Devel.
• Dr. Amanda Jones Pharm.D.,
  Sr. VP of Clinical Devel.
• Constance Ames,
  Vice President, Finance
• Myrtle S Potter,
  Director
• Randall Kaye,
  Chief Medical Officer
• Hunter R. Murdock,
  General Counsel
• John Golubieski,
  Chief Financial Officer
• Susan Mahony,